CY2013046I1 - Καινοτομος χρηση των αντισωματων αντι il-1bhta - Google Patents

Καινοτομος χρηση των αντισωματων αντι il-1bhta

Info

Publication number
CY2013046I1
CY2013046I1 CY2013046C CY2013046C CY2013046I1 CY 2013046 I1 CY2013046 I1 CY 2013046I1 CY 2013046 C CY2013046 C CY 2013046C CY 2013046 C CY2013046 C CY 2013046C CY 2013046 I1 CY2013046 I1 CY 2013046I1
Authority
CY
Cyprus
Prior art keywords
1bhta
antibodies
novel use
novel
1bhta antibodies
Prior art date
Application number
CY2013046C
Other languages
English (en)
Other versions
CY2013046I2 (el
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37806690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2013046(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY2013046I1 publication Critical patent/CY2013046I1/el
Publication of CY2013046I2 publication Critical patent/CY2013046I2/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
CY2013046C 2005-10-26 2013-12-13 Καινοτομος χρηση των αντισωματων αντι il-1bhta CY2013046I2 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73043505P 2005-10-26 2005-10-26
US74212505P 2005-12-02 2005-12-02
PCT/US2006/041479 WO2007050607A2 (en) 2005-10-26 2006-10-24 Novel use of il-1beta compounds

Publications (2)

Publication Number Publication Date
CY2013046I1 true CY2013046I1 (el) 2015-11-04
CY2013046I2 CY2013046I2 (el) 2015-11-04

Family

ID=37806690

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20121100867T CY1113378T1 (el) 2005-10-26 2012-09-24 Καινοτομος χρηση των αντισωματων αντι il-1bhta
CY2013046C CY2013046I2 (el) 2005-10-26 2013-12-13 Καινοτομος χρηση των αντισωματων αντι il-1bhta
CY20181100301T CY1120018T1 (el) 2005-10-26 2018-03-12 Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα
CY2018018C CY2018018I2 (el) 2005-10-26 2018-06-12 Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20121100867T CY1113378T1 (el) 2005-10-26 2012-09-24 Καινοτομος χρηση των αντισωματων αντι il-1bhta

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20181100301T CY1120018T1 (el) 2005-10-26 2018-03-12 Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα
CY2018018C CY2018018I2 (el) 2005-10-26 2018-06-12 Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα

Country Status (29)

Country Link
US (8) US8105587B2 (el)
EP (5) EP3332807B1 (el)
JP (4) JP2009513645A (el)
KR (3) KR101518064B1 (el)
CN (2) CN102861332A (el)
AU (1) AU2006306280B2 (el)
BR (1) BRPI0617830B8 (el)
CA (3) CA2963828A1 (el)
CY (4) CY1113378T1 (el)
DK (2) DK1940465T3 (el)
ES (3) ES2389110T3 (el)
HK (3) HK1121041A1 (el)
HU (2) HUE036973T2 (el)
IL (4) IL190545A (el)
JO (2) JO2826B1 (el)
LT (3) LT2848258T (el)
LU (2) LU92326I2 (el)
MA (1) MA29919B1 (el)
NO (2) NO345888B1 (el)
NZ (1) NZ567222A (el)
PH (2) PH12013501287B1 (el)
PL (2) PL1940465T3 (el)
PT (2) PT1940465E (el)
RU (2) RU2468817C2 (el)
SI (2) SI1940465T1 (el)
TN (1) TNSN08189A1 (el)
TR (1) TR201802449T4 (el)
TW (3) TWI537003B (el)
WO (1) WO2007050607A2 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101518064B1 (ko) 2005-10-26 2015-05-06 노파르티스 아게 Ｉｌ-1베타 화합물의 신규 용도
KR20160017119A (ko) * 2007-05-29 2016-02-15 노파르티스 아게 항-ｉｌ-1-베타 치료법에 대한 신규 적응증
AU2012203931B2 (en) * 2007-05-29 2014-04-24 Novartis Ag New indications for anti-IL-I-beta therapy
ES2398693T3 (es) * 2008-06-06 2013-03-21 Xoma Technology Ltd. Métodos para el tratamiento de la artritis reumatoide
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
CA2774326C (en) 2009-09-14 2023-11-07 Donald Bellgrau Modulation of yeast-based immunotherapy products and responses
KR20120104542A (ko) * 2009-10-15 2012-09-21 아보트 러보러터리즈 Ｉｌ?１ 결합 단백질
DK2571532T3 (en) * 2010-05-14 2017-08-28 Abbvie Inc IL-1 BINDING PROTEINS
KR20130133247A (ko) * 2010-12-21 2013-12-06 애브비 인코포레이티드 Ｉｌ-1-알파 및 -베타 이특이적 이원 가변 도메인 면역글로불린 및 이의 용도
AU2012253422B2 (en) 2011-05-10 2015-08-13 Société des Produits Nestlé S.A. Methods of disease activity profiling for personalized therapy management
WO2017153936A1 (en) 2016-03-10 2017-09-14 Novartis Ag Chemically modified messenger rna's
WO2018220588A1 (en) 2017-05-31 2018-12-06 Nestec S.A. Methods for assessing mucosal healing in crohn's disease patients
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
JP2021523894A (ja) 2018-05-09 2021-09-09 ノバルティス アーゲー カナキヌマブの使用
BR112021011351A2 (pt) 2018-12-21 2021-11-16 Novartis Ag Uso de anticorpos il-1 beta no tratamento ou prevenção de síndrome mielodisplásica
EP3898674A1 (en) 2018-12-21 2021-10-27 Novartis AG Use of il-1beta binding antibodies
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
WO2020128613A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
TWI793503B (zh) * 2020-01-20 2023-02-21 美商美國禮來大藥廠 抗IL-1β抗體
KR20230109107A (ko) * 2022-01-10 2023-07-19 (주)지아이이노베이션 글루카곤-유사 펩타이드-1 및 인터루킨-1 수용체 길항제를 포함하는 퇴행성 뇌질환 예방 또는 치료용 약학 조성물

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
WO1995016353A1 (en) 1993-12-14 1995-06-22 University Of Pittsburgh Of The Commonwealth System Of Higher Education Systemic gene treatment of connective tissue diseases
EP0937082A2 (en) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
IL144492A0 (en) 1999-02-10 2002-05-23 Interleukin Genetics Inc Therapeutics and diagnostics based on an il-1b mutation
CZ200283A3 (cs) * 1999-07-16 2002-06-12 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemis Aminobenzofenony jako inhibitory IL-1beta a TNF-alfa
ES2219388T3 (es) 1999-08-24 2004-12-01 Ariad Gene Therapeutics, Inc. 28-epi-rapalogos.
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
EP1712239A3 (en) 2000-05-12 2007-08-22 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
NZ525656A (en) 2000-11-07 2004-12-24 Novartis Ag Indolylmaleimide derivatives as protein kinase C inhibitors
JP2004536605A (ja) * 2001-07-26 2004-12-09 イーライ・リリー・アンド・カンパニー インターロイキン１β抗体
US20030049255A1 (en) 2001-08-07 2003-03-13 Sims John E. Interleukin-1 receptors in the treatment of diseases
ES2385823T3 (es) 2001-12-01 2012-08-01 Iskra Wind Turbines Ltd. Generador de corriente alterna síncrono que incorpora un mecanismo de frenado
KR200268109Y1 (ko) 2001-12-06 2002-03-15 김정훈 편평형 무정류자 진동모터
CN1697647A (zh) 2002-02-01 2005-11-16 奥默罗斯公司 用于抑制疼痛,炎症和软骨退化的溶液及方法
MXPA04007402A (es) 2002-02-01 2005-06-17 Ariad Gene Therapeutics Inc Compuestos que contienen fosforo y usos de los mismos.
BR0307691A (pt) 2002-02-11 2005-01-11 Arkion Life Sciences Composição, fator de inibição de citocina purificado e seu método de purificação, método de inibição da expressão de citocina e método para modular o sistema imunológico de um animal
PE20040079A1 (es) 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
NZ540427A (en) 2002-12-09 2008-04-30 Univ Texas Methods for selectively inhibiting janus tyrosine kinase 3 (Jak3)
CN1780855B (zh) * 2003-01-24 2011-03-30 应用分子进化公司 人IL-1β拮抗剂
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
US20050209162A1 (en) 2003-11-10 2005-09-22 Amit Roy Methods for monitoring IL-18
NZ546058A (en) 2004-01-12 2010-09-30 Ym Biosciences Australia Pty Benzimidazole and other fused ring derivatives as selective janus kinase inhibitors
EP2784090A1 (en) 2004-02-26 2014-10-01 Baylor Research Institute Compositions for the treatment of systemic onset juvenile idiopathic arthritis
JP2008500374A (ja) 2004-05-27 2008-01-10 バーテックス　ファーマシューティカルズ　インコーポレイテッド 自己炎症性疾患の処置のためのｉｃｅインヒビター
JP5022216B2 (ja) * 2004-06-04 2012-09-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法
WO2006079068A2 (en) 2005-01-20 2006-07-27 University Of Rochester Compositions and methods for studying and treating inflammatory diseases and disorders
UA94038C2 (ru) 2005-03-18 2011-04-11 Майкробиа, Инк. Продуцирование каротиноидов в маслянистых дрожжах и грибах
CN102775493B (zh) 2005-06-21 2015-10-28 爱克索马美国有限责任公司 IL-1β结合抗体及其片段
KR101518064B1 (ko) * 2005-10-26 2015-05-06 노파르티스 아게 Ｉｌ-1베타 화합물의 신규 용도

Also Published As

Publication number Publication date
JP2016020377A (ja) 2016-02-04
IL245387B (en) 2019-09-26
RU2012133522A (ru) 2014-02-20
JOP20140120B1 (ar) 2021-08-17
HK1204767A1 (en) 2015-12-04
LTPA2018506I1 (lt) 2018-06-25
IL258983B (en) 2020-10-29
PT1940465E (pt) 2012-10-03
TW200803898A (en) 2008-01-16
LU92326I9 (el) 2019-01-16
RU2008120625A (ru) 2010-01-20
TW201617097A (zh) 2016-05-16
LTC2848258I2 (lt) 2019-08-12
CA2626214A1 (en) 2007-05-03
NO20082344L (no) 2008-07-22
PT2848258T (pt) 2018-03-20
LUC00078I2 (fr) 2018-08-14
NZ567222A (en) 2011-07-29
JP2013166757A (ja) 2013-08-29
CN102861332A (zh) 2013-01-09
US8105587B2 (en) 2012-01-31
HK1252316A1 (zh) 2019-05-24
US20210147533A1 (en) 2021-05-20
JP6286403B2 (ja) 2018-02-28
CA2963828A1 (en) 2007-05-03
BRPI0617830B8 (pt) 2021-05-25
CA2898369C (en) 2017-06-20
HK1121041A1 (en) 2009-04-17
TNSN08189A1 (en) 2009-10-30
CA2626214C (en) 2016-06-21
LTC1940465I2 (lt) 2017-12-11
TWI388335B (zh) 2013-03-11
NO20200810A1 (no) 2008-07-22
AU2006306280A1 (en) 2007-05-03
PH12013501287A1 (en) 2016-02-01
PL2848258T3 (pl) 2018-06-29
CN101291693A (zh) 2008-10-22
PH12020500559A1 (en) 2021-06-14
US20150322148A1 (en) 2015-11-12
US20180201674A1 (en) 2018-07-19
BRPI0617830B1 (pt) 2020-10-20
IL258983A (en) 2018-06-28
WO2007050607A3 (en) 2007-06-28
EP3332807A3 (en) 2018-06-20
EP3332807B1 (en) 2023-02-22
IL190545A (en) 2016-09-29
EP4218815A2 (en) 2023-08-02
NO345888B1 (no) 2021-09-27
CA2898369A1 (en) 2007-05-03
JP2017206552A (ja) 2017-11-24
TWI537003B (zh) 2016-06-11
SI2848258T1 (en) 2018-03-30
HUS1800025I1 (hu) 2018-07-30
ES2944067T3 (es) 2023-06-19
KR20150013834A (ko) 2015-02-05
TR201802449T4 (tr) 2018-03-21
JP6061747B2 (ja) 2017-01-18
EP2332577A1 (en) 2011-06-15
WO2007050607A2 (en) 2007-05-03
JP2009513645A (ja) 2009-04-02
KR101518064B1 (ko) 2015-05-06
CY1120018T1 (el) 2018-12-12
HUE036973T2 (hu) 2018-08-28
US8409576B2 (en) 2013-04-02
JO2826B1 (en) 2014-09-15
EP4218815A3 (en) 2024-03-27
AU2006306280B2 (en) 2010-06-17
ES2662420T3 (es) 2018-04-06
US20130171167A1 (en) 2013-07-04
PH12013501287B1 (en) 2016-02-01
SI1940465T1 (sl) 2012-10-30
CY2013046I2 (el) 2015-11-04
RU2571563C2 (ru) 2015-12-20
NO345140B1 (no) 2020-10-12
US9649377B2 (en) 2017-05-16
PL1940465T3 (pl) 2013-01-31
CY2018018I1 (el) 2018-12-12
CN101291693B (zh) 2012-10-03
EP1940465A2 (en) 2008-07-09
EP1940465B1 (en) 2012-08-01
RU2468817C2 (ru) 2012-12-10
TW201302220A (zh) 2013-01-16
EP2848258A1 (en) 2015-03-18
TWI626056B (zh) 2018-06-11
BRPI0617830A2 (pt) 2011-08-09
KR20170038131A (ko) 2017-04-05
US20240083997A1 (en) 2024-03-14
LU92326I2 (fr) 2014-02-05
DK2848258T3 (en) 2018-03-19
IL190545A0 (en) 2008-11-03
LT2848258T (lt) 2018-02-26
MA29919B1 (fr) 2008-11-03
CY2018018I2 (el) 2018-12-12
DK1940465T3 (da) 2012-10-22
KR20080059598A (ko) 2008-06-30
US20120039910A1 (en) 2012-02-16
IL277406A (en) 2020-11-30
EP2848258B1 (en) 2017-12-13
ES2389110T3 (es) 2012-10-23
US20170218063A1 (en) 2017-08-03
CY1113378T1 (el) 2015-11-04
KR101749388B1 (ko) 2017-06-20
IL245387A0 (en) 2016-06-30
EP3332807A2 (en) 2018-06-13
US20080286266A1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
CY2013046I2 (el) Καινοτομος χρηση των αντισωματων αντι il-1bhta
NO20190202A1 (no) Anvendelse av anti-CGRP antagonist antistoff
CY2016030I1 (el) Αντισωματα εναντι της il-17
ATE483732T1 (de) Madcam-antikörper
DK1964852T3 (da) Anti-ilt7-antistof
NO20076607L (no) TWEAK - bindende antistoff
NO20071430L (no) Anti-OX4OL antistoffer
NO20055643D0 (no) Preparation of lodixanol
EP1869192A4 (en) FRAME MIXTURE OF ANTIBODIES
DE602006009980D1 (de) Biosensor
NO20043305D0 (no) Preparation of lodixanol
FI20055133A0 (fi) Iskulaite
FR2877833B1 (fr) Correcteur de lordoses
UA12593S (uk) Стела-цінник світива
ITMI20060238A1 (it) Liccio specialmente liccio di levata
FI20050571A0 (fi) Käyttömenetelmä
ITVR20050133A1 (it) Struttura di monile
ITVR20050140A1 (it) Struttura di tramezzo
ITVI20050244A1 (it) Struttura di colonnina
ITPS20050012A1 (it) Struttura di fitodepuratore
SE0402595D0 (sv) Novel use
SE0402602D0 (sv) Novel use
SE0402601D0 (sv) Novel use
SE0402600D0 (sv) Novel use
SE0402599D0 (sv) Novel use